<SEC-DOCUMENT>0001437749-21-015801.txt : 20210628
<SEC-HEADER>0001437749-21-015801.hdr.sgml : 20210628
<ACCEPTANCE-DATETIME>20210628162223
ACCESSION NUMBER:		0001437749-21-015801
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210623
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210628
DATE AS OF CHANGE:		20210628

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genprex, Inc.
		CENTRAL INDEX KEY:			0001595248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				900772347
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38244
		FILM NUMBER:		211053680

	BUSINESS ADDRESS:	
		STREET 1:		1601 TRINITY STREET, BLDG. B
		STREET 2:		SUITE 3.322
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78712
		BUSINESS PHONE:		512-537-7997

	MAIL ADDRESS:	
		STREET 1:		1601 TRINITY STREET, BLDG. B
		STREET 2:		SUITE 3.322
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78712
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>gnpx20210624_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head><meta charset="utf-8"><meta name="format-detection" content="telephone=no"><!--Created on 12/23/2020 1:33:04 AM --><meta name="generator" content="RDG HTML Converter 3.4.3.0">
	<title>gnpx20210624_8k.htm</title>

</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; text-align: center; margin: 0pt;"><b>UNITED STATES</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; text-align: center; margin: 0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; margin: 0pt;"><b>Washington, D.C. 20549</b>&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt 0pt 0pt 8pt;"><font style="font-family:Times New Roman;font-size:12pt;"><b>FORM <font style="font-family:Times New Roman;font-size:12pt;"><b>8-K</b></font></b></font></p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>CURRENT REPORT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>PURSUANT TO SECTION 13 OR 15(d)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><u>June&nbsp;23, 2021</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt 0pt 0pt 8pt;">Date of report (Date of earliest event reported)</p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:18pt;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><u>GENPREX, INC.</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;">

		<tr>
			<td style="width: 38%;">
			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;"><b><u>Delaware</u></b></p>
			</td>
			<td style="width: 24%;">
			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;"><b><u>001-38244</u></b></p>
			</td>
			<td style="width: 38%;">
			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;"><b><u>90-0772347</u></b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 38%;">
			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;">(State or other jurisdiction of</p>

			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;">incorporation or organization)</p>
			</td>
			<td style="width: 24%; vertical-align: top;">
			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;">(Commission File Number)</p>
			</td>
			<td style="width: 38%;">
			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;">(I.R.S. Employer</p>

			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;">Identification Number)</p>
			</td>
		</tr>
		<tr>
			<td style="width: 38%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="width: 24%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="width: 38%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 38%;">
			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;"><b><u>3300 Bee Cave Road, #650-227, Austin, TX</u></b></p>
			</td>
			<td style="width: 24%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="width: 38%;">
			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;"><b><u>78746</u></b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 38%;">
			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p>
			</td>
			<td style="width: 24%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="width: 38%;">
			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;">(Zip Code)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt 0pt 0pt 8pt;">Registrant&#8217;s telephone number, including area code:&nbsp;<b><u>(512) 537-7997</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not Applicable</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify; margin: 0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">&#9744;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify; margin: 0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#9744;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify; margin: 0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#9744;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify; margin: 0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#9744;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify; margin: 0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">Securities registered pursuant to Section&nbsp;12(b) of the Act:</p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;">

		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 43%;">
			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;"><b>Title of each class</b></p>
			</td>
			<td style="width: 1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;"><b>Trading</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;"><b>Symbol(s)</b></p>
			</td>
			<td style="width: 1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 43%;">
			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;"><b>Name of each exchange on which registered</b></p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 43%;">
			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;">Common Stock, par value $0.001 per share</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 12%;">
			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;">GNPX</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 43%;">
			<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt;">The Nasdaq Capital Market</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify; margin: 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b&#8211;2 of the Securities Exchange Act of 1934 (&#167;240.12b&#8211;2 of this chapter).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 8pt; text-indent: 81pt; text-align: right;">Emerging growth company&nbsp;&#9746;</p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify; margin: 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&#9746;</p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;"><b>Item 5.07. Submission of Matters to a Vote of Security Holders.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">On June 24, 2021, Genprex, Inc. (the &#8220;Company&#8221;) held its 2021 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;). As of April 26, 2021, the record date for the Annual Meeting, 47,363,729 shares of the Company&#8217;s common stock were outstanding and entitled to vote at the Annual Meeting. A total of 28,029,927 shares of common stock constituting a quorum were represented virtually in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Company&#8217;s Definitive Proxy Statement, filed with the Securities and Exchange Commission on April 30, 2021, are as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Proposal 1. Election of Directors.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify;">At the Annual Meeting, the term of the current member of the Company&#8217;s Class I director expired. The Class I director nominee was elected to serve until the next annual meeting of stockholders or until his successor has been duly elected and qualified, or until such director&#8217;s earlier resignation, removal or death. The result of the votes to elect the Class I director were as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 32%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 22%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Votes&nbsp;For</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 22%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Votes&nbsp;Withheld</p>
			</td>
			<td style="vertical-align: bottom; width: 0%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 22%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Broker&nbsp;Non-Votes</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Brent M. Longnecker</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 22%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">7,929,297</p>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 22%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2,073,930</p>
			</td>
			<td style="vertical-align: bottom; width: 0%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 22%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">18,026,700</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">At the Annual Meeting, the stockholders approved the ratification of the appointment of Daszkal Bolton LLP (&#8220;Daszkal Bolton&#8221;) as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2021. The result of the votes to approve Daszkal Bolton&nbsp;was as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Votes&nbsp;For</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Votes&nbsp;Against</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Abstention</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Broker&nbsp;Non-Votes</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">27,584,775</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">228,968</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">216,184</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:justify;margin:0pt;"><b>Item 8.01. Other Events.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Press Release</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">On June 23, 2021, the Company issued a press release announcing the initiation of its Phase 1/2 Acclaim-1 clinical trial. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.</p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;"><b>Item</b>&nbsp;<b>9.01.</b>&nbsp;&nbsp;&nbsp;&nbsp;<b> Financial Statements and Exhibits.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">(d) Exhibits</p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;">

		<tr>
			<td style="width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">99.1</p>
			</td>
			<td style="width: 95%;"><a href="ex_259789.htm" style="-sec-extract:exhibit;">Press release dated June 23, 2021.</a></td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;margin:0pt 0pt 0pt 8pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font-family:Times New Roman;font-size:10pt;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;">

		<tr>
			<td style="width: 50%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;"><b>GENPREX, INC.</b></p>
			</td>
			<td style="width: 10%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="width: 4%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="width: 35%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="width: 10%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">Date: June 28, 2021</p>
			</td>
			<td style="width: 4%;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 35%;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">/s/ Ryan Confer</p>
			</td>
			<td style="width: 10%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="width: 4%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="width: 35%;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">Ryan Confer</p>
			</td>
			<td style="width: 10%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="width: 4%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
			<td style="width: 35%;">
			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">Chief Financial Officer</p>

			<p style="font-family:Times New Roman;font-size:10pt;margin:0pt;">(Principal Financial Officer)</p>
			</td>
			<td style="width: 10%;">
			<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_259789.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">Exhibit 99.1</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA&#8482; Immunogene Therapy</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>in Combination with Tagrisso&#174; to Treat Non-Small Cell Lung Cancer Following FDA Review</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">AUSTIN, Texas &#8212; (June 23, 2021) &#8212;&nbsp;Genprex, Inc.&nbsp;(&#8220;Genprex&#8221; or the &#8220;Company&#8221;) (NASDAQ:&nbsp;GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and confirmed all comments have been addressed regarding the Company&#8217;s clinical trial protocol for the Acclaim-1 clinical trial, an open-label, multi-center Phase 1/2 clinical trial evaluating the Company&#8217;s lead drug candidate, REQORSA&#8482; Immunogene Therapy, in combination with AstraZeneca&#8217;s Tagrisso&#174; in patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Tagrisso. In January 2020, Genprex received FDA Fast Track Designation for the Acclaim-1 patient population.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In addition, the Company has engaged its first clinical site for Acclaim-1, and Genprex is continuing to work with a number of other important cancer research centers and academic institutions to select optimal study sites.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;This feedback from the FDA on our Acclaim-1 clinical trial and the engagement of our first clinical site are key milestones for Genprex,&#8221; said Rodney Varner, President and Chief Executive Officer of Genprex. &#8220;We are now looking forward to opening patient enrollment in this important study of this cutting-edge investigational gene therapy to evaluate the role it can play in the fight against lung cancer, the leading cause of cancer deaths worldwide.&#8221;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company expects the Phase 1 portion of the Acclaim-1 trial to enroll up to 18 patients at three clinical sites and for the Phase 2 portion to enroll approximately 74 patients (a 1:1 ratio of REQORSA and Tagrisso combination therapy versus Tagrisso monotherapy) at up to 15 clinical sites. The first part of the Phase 1/2 clinical trial will be a dose escalation study. The primary endpoint of the Phase 2 portion of the trial is progression-free survival, which is defined as time from randomization after first progression on Tagrisso, to first event (second progression) or death. An interim analysis will be performed at 51 events.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Genprex recently announced the&nbsp;Centralized Institutional Review Board (IRB) approval&nbsp;for the Acclaim-1 clinical trial in NSCLC. Additional information about the Acclaim-1 clinical trial can be found by visiting&nbsp;ClinicalTrials.gov.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>About Genprex, Inc.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex&#8217;s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex&#8217;s oncology program utilizes its unique, proprietary, non-viral ONCOPREX&#174; Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform for cancer. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The Company&#8217;s lead product candidate, REQORSA&#8482; (<i>quaratusugene ozeplasmid</i>), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca&#8217;s Tagrisso&#174; (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso<i>.</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">For more information, please visit the Company&#8217;s web site at&nbsp;www.genprex.com&nbsp;or follow Genprex on&nbsp;Twitter,&nbsp;Facebook&nbsp;and&nbsp;LinkedIn.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Cautionary Language Concerning Forward-Looking Statements</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Statements contained in this press release regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex&#8217;s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under &#8220;Item 1A &#8211; Risk Factors&#8221; in Genprex&#8217;s Annual Report on Form 10-K.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex&#8217;s clinical trials and regulatory approvals; the effect of Genprex&#8217;s product candidates, alone and in combination with other therapies, on cancer and diabetes;&nbsp;Genprex&#8217;s future growth and financial status; Genprex&#8217;s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex&#8217;s intellectual property and licenses.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Genprex, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">(877) 774-GNPX (4679)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Investor Relations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">GNPX Investor Relations</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">(877) 774-GNPX (4679) ext. #2</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">investors@genprex.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Media Contact</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Genprex Media Relations</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Kalyn Dabbs</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">(877) 774-GNPX (4679) ext. #3</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">media@genprex.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
